Nouvelle déclaration d'incident
No de la demande: 2011-6099
Numéro de référence du titulaire d'homologation: PROSAR Case #: 1-28046592
Nom du titulaire (nom légal complet, aucune abbréviation): Syngenta Crop Protection Canada, Inc.
Adresse: 140 Research Lane, Research Park
Ville: Guelph
État: Ontario
Pays: Canada
Code postal /Zip: N1G4Z3
Incident chez l'humain
Pays: UNITED STATES
État: VIRGINIA
ARLA No d'homologation ARLA No de la demande d'homologation EPA No d'homologation. 100-1232
Nom du produit: Demand EZ Insecticide
Liquide
Oui
Inconnu
Site: Res. - Out Home / Rés - à l'ext.maison
Inconnu
Personne affectée
Sexe: Femme
Âge: >19 <=64 yrs / >19 <=64 ans
Système
Unknown / Inconnu
Oui
Oui
6
Day(s) / Jour(s)
Non professionnel
Contact avec la zone traitée
Temps écoulé entre l'application et l'exposition (contact) 2
Day(s) / Jour(s)
Quelle était l'activité? lawn care in application area
Inconnu
Inconnu
Unknown / Inconnu
>2 hrs <=8 hrs / > 2 h < = 8 h
1-28046592- The reporter, a home owner, indicated potential exposure to an insecticidal product containing the active ingredient lambda-cyhalothrin. The reporter, a (age) year woman, stated the product was applied by a commercial pest control operator to the exterior of her home one month prior to her initial contact with the registrant. She was unable to provide further detail regarding the application. She stated she did not enter the application area for two days at which point she spent time trimming trees in the application area. The reporter indicated the day of application she noted the onset of fatigue, dizziness, difficulty walking, and a drunken feeling. Throughout the subsequent week she was dizzy, nauseated, and tired, but somewhat improved. The caller at that point described entering the application area two days after application to trim trees on her property. She described one day after entering the application area worsening of the dizziness and fatigue that persisted throughout the week. 25 days after the application date she reported she was unable to catch her breath and was so dizzy she had difficulty standing and consequently went to the hospital where she was admitted. She reported gradual improvement while admitted and described being on supplemental oxygen though she was unable to describe any addition treatments or diagnostics done. She did comment the doctors were unable to discover the cause for her symptoms. She reported being discharged six days later, but had found the dizziness and shortness of breath were worsening after her release. She described seeing another physician two days after her discharge from the hospital and was given an inhaler for her respiratory symptoms. The caller was throughout this description unable to describe a discreet exposure incident. The caller was advised the symptoms and time line of her symptoms were inconsistent with toxicity profile of the active ingredient or finished product. She was advised to further consult her doctor in efforts to discover the cause of her discomfort. Follow up was obtained from the reporter one week after her initial report at which point she described visits to an otolaryngologist and neurologist. She indicated she had undergone numerous tests and the only abnormal finding was an elevated anion gap. She indicated she would go back to her primary physician at this point. The caller was again advised that the symptoms and time line were inconsistent with the profile of this active ingredient and the finished product. She was encouraged to work with her doctors. The case was not followed further due the inconsistency. No further information is available.
Modérée